MEDIA

Press Release January 14, 2020

MSI Methylation Sciences, Inc. (“MSI”) Update on its Dispute with Quark Venture Inc., now known as 1032951 B.C. Ltd. (“Quark”): Quark’s Court of Appeal Application was Denied, and Quark has Filed a NOI to make a Proposal to its Creditors

More

Press Release April 15, 2019

MSI Methylation Sciences, Inc. (MSI) Update on Recent BC Supreme Court Order for Quark Venture Inc. (Quark) to Pay MSI $20 million USD

More

Press Release January 27, 2016

MSI Methylation Sciences Inc. (MSI) Announces Results From the Horizon Phase 2 Trial for its Novel Treatment, MSI-195, for Major Depressive Disorder (MDD)

More

Press Release August 25, 2015

MSI Methylation Sciences Inc. (MSI) Treats the Last Patient in its Horizon Trial and Receives Four Patents to Support its Proprietary Treatment Strada™ for Major Depressive Disorder (MDD)

More

Press Release May 7, 2015

MSI Methylation Sciences Inc. (MSI) Completes Recruitment of Phase 2 Trial for its Novel Treatment Strada™ for Major Depressive Disorder (MDD)

More